# reload+after+2024-01-21 19:36:13.268060
address1§Alderley Park, Block 24
address2§Suite 24G13 Congleton Road
city§Nether Alderley
zip§SK10 4TG
country§United Kingdom
phone§44 1625 315 090
website§https://evgen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
fullTimeEmployees§10
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Huw  Jones BSc, Ph.D.', 'age': 63, 'title': 'CEO & Executive Director', 'yearBorn': 1960, 'fiscalYear': 2023, 'totalPay': 304730, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Toni  Hänninen', 'title': 'CFO & Director', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Helen  Kuhlman', 'title': 'Chief Business Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Glen  Clack FFPM, M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.429
priceToSalesTrailing12Months§5.658494
currency§GBp
forwardEps§-0.2
exchange§LSE
quoteType§EQUITY
shortName§EVGEN PHARMA PLC ORD 0.25P
longName§Evgen Pharma plc
firstTradeDateEpochUtc§1445410800
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§22622b03-1082-3203-beda-f4b789cbd092
targetHighPrice§18.0
targetLowPrice§18.0
targetMeanPrice§18.0
targetMedianPrice§18.0
recommendationKey§none
numberOfAnalystOpinions§1
quickRatio§10.386
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
